Literature DB >> 17634716

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome accompanied by Parkinson's disease.

Eiichi Ito1, Hiroshi Okamoto, Atsuko Mochizuki, Kuniko Ohara, Maiko Kato, Yutaka Terashima, Eiichi Tanaka, Kae Takagi, Shinichiro Uchiyama, Makoto Iwata.   

Abstract

We encountered two cases of RS3PE (remitting seronegative symmetrical synovitis with pitting edema) syndrome accompanied by Parkinson's disease (PD). Although the etiology of RS3PE syndrome is still unknown, several possible associations, such as malignancies and viral infections, have been reported; RS3PE syndrome is thought to be an autoimmune-mediated disorder. The present patients did not have any factors which are reported to be associated with RS3PE. Whether or not the complication of PD and RS3PE syndrome is incidental needs to be further examined, and we discuss here the possible cause of association between PD and RS3PE syndrome, including dopamine agonists one of the anti-PD medications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634716     DOI: 10.2169/internalmedicine.46.0029

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Impact of low-dose prednisolone on refractory pitting edema manifesting remitting seronegative symmetrical synovitis with pitting edema syndrome.

Authors:  Yuhei Nojima; Madoka Ihara; Hidenori Adachi; Tetsuya Kurimoto; Shinsuke Nanto
Journal:  J Cardiol Cases       Date:  2016-07-15

2.  Remitting seronegative symmetrical synovitis with pitting edema following acute intracranial hemorrhage.

Authors:  Deng-Ho Yang; Deh-Ming Chang; Jenn-Haung Lai; Guo-Shu Huang; Wei-Chou Chang; Tsung-Yun Hou
Journal:  Rheumatol Int       Date:  2009-10-14       Impact factor: 2.631

3.  Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Complicated with Organizing Pneumonia.

Authors:  Chiaki Hosoda; Takashi Ishiguro; Yasuhiro Morimoto; Atsuki Furube; Taisuke Isono; Yoshihiko Shimizu; Noboru Takayanagi
Journal:  Intern Med       Date:  2020-01-17       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.